? Head and neck cancer is the sixth most common cancer worldwide, the seventh most common solid tumor in the United States. The incidence of head and neck cancer in African American men has been approximately two times higher than that of non African American men with a lower 5-year relative survival (36.2% vs. 47.6%). Howard University Medical Institutions is a minority-serving educational institution and medical center that is an important educational and clinical resource in the Washington DC/ Baltimore metropolitan area and serves a large community of low-income African American patients. However, recruitment and support for translational research efforts at Howard University has significant challenges. The goal of this proposal is to create a collaborative environment to enhance translational research and education related to head and neck cancer at the Howard University Medical Institutions through a highly collaborative effort between the Howard University Medical Institutions and the Head and Neck Cancer Center at the Johns Hopkins Medical Institutions. This collaboration is focused on translational research and research training as well as educational efforts focused on enhancing head and neck cancer translational research and impact on the Howard Medical Institutions community.
Specific aims will be: 1) to support collaborative cancer research projects between the Howard University Medical Institutions and the Head and Neck Cancer Center and Sidney Kimmel Cancer Center at Johns Hopkins 2) to provide collaborative training and mentoring program for promoting Howard medical and dental students and faculty in cancer research, 3) to establish education programs that advance the knowledge of translational cancer research as it applies to etiology, prevention, diagnosis, and treatment of head and neck cancer in the context of minority-serving institutions.
These aims will be promoted and coordinated in a synergistic manner, such that they reinforce the creation of a culture of collaborative translational research within the Howard University Cancer Center as well as an effective long-term partnership with investigators at the Johns Hopkins Medical Institutions. These goals will be pursued by directed mentorship of individuals at Howard Medical Institutions to develop as independent investigators via traditional mechanisms of the National Cancer Institute. ? ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Exploratory Grants (P20)
Project #
5P20CA118770-02
Application #
7129011
Study Section
Special Emphasis Panel (ZCA1-SRRB-Y (O1))
Program Officer
Aguila, H Nelson
Project Start
2005-09-30
Project End
2009-08-31
Budget Start
2006-09-01
Budget End
2007-08-31
Support Year
2
Fiscal Year
2006
Total Cost
$195,243
Indirect Cost
Name
Howard University
Department
Dentistry
Type
Schools of Dentistry
DUNS #
056282296
City
Washington
State
DC
Country
United States
Zip Code
20059
Zhao, Yuan; Ling, Zhiqiang; Hao, Yubin et al. (2017) MiR-124 acts as a tumor suppressor by inhibiting the expression of sphingosine kinase 1 and its downstream signaling in head and neck squamous cell carcinoma. Oncotarget 8:25005-25020
Hauser, Belinda; Zhao, Yuan; Pang, Xiaowu et al. (2015) Functions of MiRNA-128 on the regulation of head and neck squamous cell carcinoma growth and apoptosis. PLoS One 10:e0116321
Zhou, Yanfei; Sridhar, Rajagopalan; Shan, Liang et al. (2012) Loperamide, an FDA-approved antidiarrhea drug, effectively reverses the resistance of multidrug resistant MCF-7/MDR1 human breast cancer cells to doxorubicin-induced cytotoxicity. Cancer Invest 30:119-25
Cai, Chunxiao; Ashktorab, Hassan; Pang, Xiaowu et al. (2012) MicroRNA-211 expression promotes colorectal cancer cell growth in vitro and in vivo by targeting tumor suppressor CHD5. PLoS One 7:e29750
Hao, Yubin; Zhao, Yuan; Zhao, Xiaoyun et al. (2011) Improvement of prostate cancer detection by integrating the PSA test with miRNA expression profiling. Cancer Invest 29:318-24
Hao, Yubin; Gu, Xinbin; Zhao, Yuan et al. (2011) Enforced expression of miR-101 inhibits prostate cancer cell growth by modulating the COX-2 pathway in vivo. Cancer Prev Res (Phila) 4:1073-83
Peng, Shiwen; Monie, Archana; Pang, Xiaowu et al. (2011) Vascular disrupting agent DMXAA enhances the antitumor effects generated by therapeutic HPV DNA vaccines. J Biomed Sci 18:21
Zeng, Qi; Peng, Shiwen; Monie, Archana et al. (2011) Control of cervicovaginal HPV-16 E7-expressing tumors by the combination of therapeutic HPV vaccination and vascular disrupting agents. Hum Gene Ther 22:809-19
Zhao, Yuan; Hao, Yubin; Ji, Hongguang et al. (2010) Combination effects of salvianolic acid B with low-dose celecoxib on inhibition of head and neck squamous cell carcinoma growth in vitro and in vivo. Cancer Prev Res (Phila) 3:787-96
Hao, Yubin; Xie, Tianpei; Korotcov, Alexandru et al. (2009) Salvianolic acid B inhibits growth of head and neck squamous cell carcinoma in vitro and in vivo via cyclooxygenase-2 and apoptotic pathways. Int J Cancer 124:2200-9

Showing the most recent 10 out of 14 publications